{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:53:54Z","timestamp":1794002034855,"version":"4.8.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Amplification of 1q21 correlates with increased sensitivity to MCL-1 inhibitor S63845 in primary MM cells. Poor-prognosis MM is particularly sensitive to MCL-1 inhibition, partially independent of 1q21 amplification status.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000702","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T16:34:07Z","timestamp":1576773247000},"page":"4202-4214","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":91,"title":["Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting"],"prefix":"10.1182","volume":"3","author":[{"given":"Anne","family":"Slomp","sequence":"first","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Moesbergen","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-nan","family":"Gong","sequence":"additional","affiliation":[{"name":"Cancer and Hematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cuenca","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"von dem Borne","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4873","authenticated-orcid":false,"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer and Hematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-3820","authenticated-orcid":false,"given":"Victor","family":"Peperzak","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"issue":"1","key":"2019121911324349600_B1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2019121911324349600_B2","doi-asserted-by":"crossref","first-page":"f3863","DOI":"10.1136\/bmj.f3863","article-title":"Multiple myeloma","volume":"346","author":"Smith","year":"2013","journal-title":"BMJ"},{"issue":"20","key":"2019121911324349600_B3","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"2019121911324349600_B4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3389\/fimmu.2018.01228","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"9","author":"Plesner","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2019121911324349600_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"2019121911324349600_B6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2019121911324349600_B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019121911324349600_B8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuill\u00e8me-Toumi","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"2019121911324349600_B9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2019121911324349600_B10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"2018","journal-title":"Front Oncol"},{"key":"2019121911324349600_B11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/DDDT.S109325","article-title":"Development of venetoclax for therapy of lymphoid malignancies","volume":"11","author":"Zhu","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"22","key":"2019121911324349600_B12","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2019121911324349600_B13","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","article-title":"Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14)","volume":"132","author":"Cleynen","year":"2018","journal-title":"Blood"},{"issue":"7626","key":"2019121911324349600_B14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2019121911324349600_B15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.21516","article-title":"Selective targeting of antiapoptotic BCL-2 proteins in cancer","volume":"39","author":"Timucin","year":"2019","journal-title":"Med Res Rev"},{"issue":"5","key":"2019121911324349600_B16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019121911324349600_B17","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/sj.bjc.6605981","article-title":"BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma","volume":"103","author":"Bodet","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"2019121911324349600_B18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2019121911324349600_B19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"47","key":"2019121911324349600_B20","doi-asserted-by":"crossref","first-page":"77326","DOI":"10.18632\/oncotarget.12643","article-title":"A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications","volume":"7","author":"Jakubikova","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2019121911324349600_B21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"2019121911324349600_B22","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019121911324349600_B23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2006.06467.x","article-title":"Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma","volume":"136","author":"Agnelli","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"2019121911324349600_B24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"279","key":"2019121911324349600_B25","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"issue":"8","key":"2019121911324349600_B26","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41375-019-0421-0","article-title":"BCL2 blockade overcomes MCL1 resistance in multiple myeloma","volume":"33","author":"Siu","year":"2019","journal-title":"Leukemia"},{"issue":"22","key":"2019121911324349600_B27","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019121911324349600_B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.1984.2.1.51","article-title":"Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders","volume":"2","author":"Garewal","year":"1984","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019121911324349600_B29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.hoc.2007.08.010","article-title":"Prognostic factors and staging in multiple myeloma","volume":"21","author":"Fonseca","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"2019121911324349600_B30","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25):6281]","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019121911324349600_B31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"issue":"25","key":"2019121911324349600_B32","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019121911324349600_B33","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"14","key":"2019121911324349600_B34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS Lett"},{"key":"2019121911324349600_B35","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma [published online ahead of print 18 July 2019]","author":"Algar\u00edn","journal-title":"Haematologica"},{"issue":"1","key":"2019121911324349600_B36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1101\/gad.14.1.23","article-title":"Mcl-1 deficiency results in peri-implantation embryonic lethality","volume":"14","author":"Rinkenberger","year":"2000","journal-title":"Genes Dev"},{"issue":"5712","key":"2019121911324349600_B37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.1106114","article-title":"Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells","volume":"307","author":"Opferman","year":"2005","journal-title":"Science"},{"issue":"12","key":"2019121911324349600_B38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev"},{"issue":"4","key":"2019121911324349600_B39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mcn.2012.02.003","article-title":"Mcl-1 regulates the survival of adult neural precursor cells","volume":"49","author":"Malone","year":"2012","journal-title":"Mol Cell Neurosci"},{"issue":"6007","key":"2019121911324349600_B40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1126\/science.1191793","article-title":"Mcl-1 is essential for germinal center formation and B cell memory","volume":"330","author":"Vikstrom","year":"2010","journal-title":"Science"},{"issue":"8","key":"2019121911324349600_B41","doi-asserted-by":"crossref","first-page":"e2345","DOI":"10.1038\/cddis.2016.237","article-title":"MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL","volume":"7","author":"Vikstr\u00f6m","year":"2016","journal-title":"Cell Death Dis"},{"issue":"3","key":"2019121911324349600_B42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells [published correction appears in Nat Immunol. 2013;14(8):877]","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"issue":"9","key":"2019121911324349600_B43","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"2019121911324349600_B44","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"12","key":"2019121911324349600_B45","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019121911324349600_B46","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematological cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"2019121911324349600_B47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"102","key":"2019121911324349600_B48","doi-asserted-by":"crossref","first-page":"37777","DOI":"10.18632\/oncotarget.26540","article-title":"Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells","volume":"9","author":"Grundy","year":"2018","journal-title":"Oncotarget"},{"issue":"14","key":"2019121911324349600_B49","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4202\/1549451\/advancesadv2019000702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4202\/1549451\/advancesadv2019000702.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:51:26Z","timestamp":1665273086000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/24\/4202\/429970\/Multiple-myeloma-with-1q21-amplification-is-highly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,19]]},"references-count":49,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000702","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,19]]}}}